Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$1.46 – $1.53
0% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $159.08B | $186.57B | $191.91B | $215.82B | $231.98B | $260.30B | $275.25B | $283.58B |
| Cost of revenue | $136.52B | $159.75B | $164.47B | $187.28B | $201.49B | $228.97B | $244.62B | $253.16B |
| Gross profit | $22.56B | $26.81B | $27.44B | $28.54B | $30.49B | $31.33B | $30.63B | $30.42B |
| Gross margin | 14.2% | 14.4% | 14.3% | 13.2% | 13.1% | 12.0% | 11.1% | 10.7% |
| R&D | $1.06B | $1.35B | $1.66B | $1.99B | $2.11B | $2.20B | $2.39B | $2.34B |
| Operating income | $5.21B | $8.93B | $7.18B | $8.21B | $9.01B | $7.67B | $8.14B | $9.94B |
| EBITDA | $6.72B | $9.35B | $9.94B | $11.27B | $12.42B | $10.90B | $12.06B | $14.37B |
| Net income | $3.88B | $4.08B | $4.50B | $5.09B | $5.62B | $3.77B | $4.55B | $5.72B |
| Net margin | 2.4% | 2.2% | 2.3% | 2.4% | 2.4% | 1.4% | 1.7% | 2.0% |
| EPS (diluted) | 1.37 | 1.44 | 1.58 | 1.79 | 1.61 | 1.02 | 1.23 | 1.54 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $296.8B | $1.41 | $1.34–$1.45 | 1 |
| 2027 | $313.8B | $1.51 | $1.44–$1.56 | 1 |
| 2028 | $335.7B | $1.64 | $1.57–$1.69 | 1 |
Forward consensus · source: Financial Modeling Prep
SHANGHAI PHARMS HL H ORD
No one on the platform currently holds SHPMF.
No tracked institution reports a position in SHPMF as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-07-16 | $0.4048 | 2026-08-24 |
| 2025-12-31 | $0.1321 | 2026-02-06 |
| 2025-07-17 | $0.3170 | 2025-08-25 |
| 2024-09-19 | $0.0874 | 2024-10-25 |
| 2024-07-19 | $0.4407 | 2024-08-27 |
| 2023-07-18 | $0.6638 | 2023-08-28 |
No one on the platform has traded SHPMF yet.
| +0.00% |
| $8.7B |
| — |
| KYKOFKyowa Kirin Co., Ltd. | $14.20 | -1.59% | $7.4B | — |
| SHTDFSinopharm Group Co. Ltd. | $2.13 | +0.00% | $6.6B | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 1.2× earnings vs its 1.1× historical median P/E.
Fair value ≈ $1.30 · price $1.46 today
Fair-value line = the stock's median historical P/E × earnings. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.